Site Map

CEA blood test

Carcinoembryonic antigen blood test

The carcinoembryonic antigen (CEA) test measures the level of CEA in the blood. CEA is a protein normally found in the tissue of a developing baby in the womb. The blood level of this protein disappears or becomes very low after birth. In adults, an abnormal level of CEA may be a sign of cancer.

Images

Blood test

How the Test is Performed

A blood sample is needed.

How to Prepare for the Test

Smoking may increase the CEA level. If you smoke, your doctor may tell you to avoid doing so for a short time before the test.

How the Test will Feel

When the needle is inserted to draw blood, some people feel moderate pain. Others feel only a prick or stinging. Afterward, there may be some throbbing or a slight bruise. This soon goes away.

Why the Test is Performed

This test is done to monitor the response to treatment and then to check for the return of colon and other cancers such as medullary thyroid cancer and cancers of the rectum, lung, breast, liver, pancreas, stomach, and ovaries.

It is not used as a screening test for cancer and should not be done unless a diagnosis of cancer has been made.

Normal Results

The normal range is 0 to 2.5 ng/mL (0 to 2.5 µg/L).

In smokers, slightly higher values may be considered normal (0 to 5 ng/mL, or 0 to 5 µg/L).

What Abnormal Results Mean

A high CEA level in a person recently treated for certain cancers may mean the cancer has returned. A higher than normal level may be due to the following cancers:

Higher than normal CEA level alone cannot diagnose a new cancer. Further testing is needed.

An increased CEA level may also be due to:

Risks

There is little risk involved with having your blood taken. Veins and arteries vary in size from one person to another and from one side of the body to the other. Taking blood from some people may be more difficult than from others.

Other risks associated with having blood drawn are slight but may include:

Related Information

Protein in diet
Colorectal cancer
Cancer
Breast cancer
Lung cancer - small cell
Pancreatic cancer
Thyroid cancer
Ulcerative colitis
Diverticulitis
Acute cholecystitis
Cirrhosis
Liver disease
Peptic ulcer
Pulmonary angiography

References

Franklin WA, Aisner DL, Davies KD, et al. Pathology, biomarkers, and molecular diagnostics. In: Niederhuber JE, Armitage JO, Kastan MB, Doroshow JH, Tepper JE, eds. Abeloff's Clinical Oncology. 6th ed. Philadelphia, PA: Elsevier; 2020:chap 15.

Jain S, Pincus MR, Bluth MH, McPherson RA, Bowne WB, Lee P. Diagnosis and management of cancer using serologic and other body fluid markers. In: McPherson RA, Pincus MR, eds. Henry's Clinical Diagnosis and Management by Laboratory Methods. 23rd ed. St Louis, MO: Elsevier; 2017:chap 74.

BACK TO TOP

Review Date: 7/8/2019  

Reviewed By: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

ADAM Quality Logo

A.D.A.M., Inc. is accredited by URAC, for Health Content Provider (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics. This site complies with the HONcode standard for trustworthy health information: verify here.

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- 2021 A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

A.D.A.M. content is best viewed in IE9 or above, Firefox and Google Chrome browser.